glp 1 drugs for sleep apnea glp-1 Insurance companies scrambling to support need for GLP-1 drugs glp 1 drugs sleep apnea

Sleep Disorders Obstructive sleep apnea (OSA) represents a significant clinical breakthrough for GLP-1 RAs in sleep medicine, culminating in the historic FDA approval of tirzepatide (Zepbound) on December 20, 2024, as the first medication specifically indicated for moderate-to-severe OSA in adults with obesity [154]

Thus, Basaglar is cheaper upfront, though Ozempics weekly dosing and weight loss benefits may reduce long-term healthcare expenses

22 Pharmacists can play a pivotal role in addressing these challenges by proactively discussing medication access with patients and tailoring solutions based on individual factors such as drug type, indication, insurance coverage, and personal circumstances

Discontinuation rates due to adverse events were 12.2% and 18.2% with retatrutide 9 mg and 12 mg, respectively, compared to 4.0% with placebo

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials